Cargando…

A snapshot of the prevalence of dihydropteroate synthase-431V mutation and other sulfadoxine-pyrimethamine resistance markers in Plasmodium falciparum isolates in Nigeria

BACKGROUND: Malaria is a major public health issue with substantial risks among vulnerable populations. Currently, the World Health Organization (WHO) recommends SP-IPTp in the second and third trimesters. However, the efficacy of SP-IPTp is threatened by the emergence of sulfadoxine-pyrimethamine r...

Descripción completa

Detalles Bibliográficos
Autores principales: Adegbola, Adebanjo J., Ijarotimi, Omotade A., Ubom, Akaninyene E., Adesoji, Bukola A., Babalola, Olajide E., Hocke, Emma F., Hansson, Helle, Mousa, Andria, Bolaji, Oluseye O., Alifrangis, Michael, Roper, Cally
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976540/
https://www.ncbi.nlm.nih.gov/pubmed/36859238
http://dx.doi.org/10.1186/s12936-023-04487-5
_version_ 1784899108150968320
author Adegbola, Adebanjo J.
Ijarotimi, Omotade A.
Ubom, Akaninyene E.
Adesoji, Bukola A.
Babalola, Olajide E.
Hocke, Emma F.
Hansson, Helle
Mousa, Andria
Bolaji, Oluseye O.
Alifrangis, Michael
Roper, Cally
author_facet Adegbola, Adebanjo J.
Ijarotimi, Omotade A.
Ubom, Akaninyene E.
Adesoji, Bukola A.
Babalola, Olajide E.
Hocke, Emma F.
Hansson, Helle
Mousa, Andria
Bolaji, Oluseye O.
Alifrangis, Michael
Roper, Cally
author_sort Adegbola, Adebanjo J.
collection PubMed
description BACKGROUND: Malaria is a major public health issue with substantial risks among vulnerable populations. Currently, the World Health Organization (WHO) recommends SP-IPTp in the second and third trimesters. However, the efficacy of SP-IPTp is threatened by the emergence of sulfadoxine-pyrimethamine resistant malaria parasites due to single nucleotide polymorphisms in the Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthetase genes. This study aimed to assess the current prevalence of Pfdhfr/Pfdhps mutations in P. falciparum isolates collected from individuals residing in Ile-Ife, Nigeria, and also present maps of the prevalence of Pfdhps 431V and 581G within Nigeria and surrounding countries. METHODS: Between October 2020 and April 2021, samples were collected as dried blood spots among 188 participants who showed malaria positivity with a histidine-rich-protein-based rapid diagnostic test (RDT). Nested PCR assays were used to confirm falciparum in the samples with RDT positivity, and to amplify fragments of the Pfdhfr/Pfdhps genes followed by targeted amplicon sequencing. Published data since 2007 on the prevalence of the Pfdhps genotypes in Nigeria and the neighbouring countries were used to produce maps to show the distribution of the mutant genotypes. RESULTS: Only 74 and 61 samples were successfully amplified for the Pfdhfr and Pfdhps genes, respectively. At codons resulting in N51I, C59R, and S108N, Pfdhfr carried mutant alleles of 97.3% (72/74), 97.3% (72/74) and 98.6% (73/74), respectively. The Pfdhps gene carried mutations at codons resulting in amino acid changes at 431–436-437–540-581–613; I431V [45.9%, (28/61)], A581G [31.1% (19/61)] and A613S [49.2% (30/61)]. Constructed haplotypes were mainly the triple Pfdhfr mutant 51I-59R-108N (95.9%), and the most common haplotypes observed for the Pfdhps gene were the ISGKAA (32.8%), ISGKGS (8.2%), VAGKAA (14.8%), VAGKAS (9.8%) and VAGKGS (14.8%). In the context of the previously published data, a high prevalence of 431V/581G mutations was found in the study population. It seems quite evident that the Pfdhps 431V, 581G and 613S often co-occur as Pfdhps-VAGKGS haplotype. CONCLUSION: This study showed that the prevalence of VAGKGS haplotype seems to be increasing in prevalence. If this is similar in effect to the emergence of 581G in East Africa, the efficacy of SP-IPTp in the presence of these novel Pfdhps mutants should be re-assessed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04487-5.
format Online
Article
Text
id pubmed-9976540
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99765402023-03-02 A snapshot of the prevalence of dihydropteroate synthase-431V mutation and other sulfadoxine-pyrimethamine resistance markers in Plasmodium falciparum isolates in Nigeria Adegbola, Adebanjo J. Ijarotimi, Omotade A. Ubom, Akaninyene E. Adesoji, Bukola A. Babalola, Olajide E. Hocke, Emma F. Hansson, Helle Mousa, Andria Bolaji, Oluseye O. Alifrangis, Michael Roper, Cally Malar J Research BACKGROUND: Malaria is a major public health issue with substantial risks among vulnerable populations. Currently, the World Health Organization (WHO) recommends SP-IPTp in the second and third trimesters. However, the efficacy of SP-IPTp is threatened by the emergence of sulfadoxine-pyrimethamine resistant malaria parasites due to single nucleotide polymorphisms in the Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthetase genes. This study aimed to assess the current prevalence of Pfdhfr/Pfdhps mutations in P. falciparum isolates collected from individuals residing in Ile-Ife, Nigeria, and also present maps of the prevalence of Pfdhps 431V and 581G within Nigeria and surrounding countries. METHODS: Between October 2020 and April 2021, samples were collected as dried blood spots among 188 participants who showed malaria positivity with a histidine-rich-protein-based rapid diagnostic test (RDT). Nested PCR assays were used to confirm falciparum in the samples with RDT positivity, and to amplify fragments of the Pfdhfr/Pfdhps genes followed by targeted amplicon sequencing. Published data since 2007 on the prevalence of the Pfdhps genotypes in Nigeria and the neighbouring countries were used to produce maps to show the distribution of the mutant genotypes. RESULTS: Only 74 and 61 samples were successfully amplified for the Pfdhfr and Pfdhps genes, respectively. At codons resulting in N51I, C59R, and S108N, Pfdhfr carried mutant alleles of 97.3% (72/74), 97.3% (72/74) and 98.6% (73/74), respectively. The Pfdhps gene carried mutations at codons resulting in amino acid changes at 431–436-437–540-581–613; I431V [45.9%, (28/61)], A581G [31.1% (19/61)] and A613S [49.2% (30/61)]. Constructed haplotypes were mainly the triple Pfdhfr mutant 51I-59R-108N (95.9%), and the most common haplotypes observed for the Pfdhps gene were the ISGKAA (32.8%), ISGKGS (8.2%), VAGKAA (14.8%), VAGKAS (9.8%) and VAGKGS (14.8%). In the context of the previously published data, a high prevalence of 431V/581G mutations was found in the study population. It seems quite evident that the Pfdhps 431V, 581G and 613S often co-occur as Pfdhps-VAGKGS haplotype. CONCLUSION: This study showed that the prevalence of VAGKGS haplotype seems to be increasing in prevalence. If this is similar in effect to the emergence of 581G in East Africa, the efficacy of SP-IPTp in the presence of these novel Pfdhps mutants should be re-assessed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04487-5. BioMed Central 2023-03-01 /pmc/articles/PMC9976540/ /pubmed/36859238 http://dx.doi.org/10.1186/s12936-023-04487-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Adegbola, Adebanjo J.
Ijarotimi, Omotade A.
Ubom, Akaninyene E.
Adesoji, Bukola A.
Babalola, Olajide E.
Hocke, Emma F.
Hansson, Helle
Mousa, Andria
Bolaji, Oluseye O.
Alifrangis, Michael
Roper, Cally
A snapshot of the prevalence of dihydropteroate synthase-431V mutation and other sulfadoxine-pyrimethamine resistance markers in Plasmodium falciparum isolates in Nigeria
title A snapshot of the prevalence of dihydropteroate synthase-431V mutation and other sulfadoxine-pyrimethamine resistance markers in Plasmodium falciparum isolates in Nigeria
title_full A snapshot of the prevalence of dihydropteroate synthase-431V mutation and other sulfadoxine-pyrimethamine resistance markers in Plasmodium falciparum isolates in Nigeria
title_fullStr A snapshot of the prevalence of dihydropteroate synthase-431V mutation and other sulfadoxine-pyrimethamine resistance markers in Plasmodium falciparum isolates in Nigeria
title_full_unstemmed A snapshot of the prevalence of dihydropteroate synthase-431V mutation and other sulfadoxine-pyrimethamine resistance markers in Plasmodium falciparum isolates in Nigeria
title_short A snapshot of the prevalence of dihydropteroate synthase-431V mutation and other sulfadoxine-pyrimethamine resistance markers in Plasmodium falciparum isolates in Nigeria
title_sort snapshot of the prevalence of dihydropteroate synthase-431v mutation and other sulfadoxine-pyrimethamine resistance markers in plasmodium falciparum isolates in nigeria
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976540/
https://www.ncbi.nlm.nih.gov/pubmed/36859238
http://dx.doi.org/10.1186/s12936-023-04487-5
work_keys_str_mv AT adegbolaadebanjoj asnapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT ijarotimiomotadea asnapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT ubomakaninyenee asnapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT adesojibukolaa asnapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT babalolaolajidee asnapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT hockeemmaf asnapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT hanssonhelle asnapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT mousaandria asnapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT bolajioluseyeo asnapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT alifrangismichael asnapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT ropercally asnapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT adegbolaadebanjoj snapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT ijarotimiomotadea snapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT ubomakaninyenee snapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT adesojibukolaa snapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT babalolaolajidee snapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT hockeemmaf snapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT hanssonhelle snapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT mousaandria snapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT bolajioluseyeo snapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT alifrangismichael snapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria
AT ropercally snapshotoftheprevalenceofdihydropteroatesynthase431vmutationandothersulfadoxinepyrimethamineresistancemarkersinplasmodiumfalciparumisolatesinnigeria